Author
Rick Popert
Other affiliations: St Thomas' Hospital, London Bridge Hospital, King's College London ...read more
Bio: Rick Popert is an academic researcher from Guy's Hospital. The author has contributed to research in topics: Prostate cancer & Prostatectomy. The author has an hindex of 24, co-authored 102 publications receiving 1791 citations. Previous affiliations of Rick Popert include St Thomas' Hospital & London Bridge Hospital.
Topics: Prostate cancer, Prostatectomy, Prostate biopsy, Biopsy, Brachytherapy
Papers published on a yearly basis
Papers
More filters
Institute of Cancer Research1, University of Salford2, Cardiff University3, Copenhagen University Hospital4, University Health Network5, St James's University Hospital6, Queen's University7, University College London8, Université de Montréal9, University of Wolverhampton10, East Kent Hospitals University Nhs Foundation Trust11, Barking, Havering and Redbridge University Hospitals NHS Trust12, Royal Surrey County Hospital13, Southampton General Hospital14, Maidstone and Tunbridge Wells NHS Trust15, University Hospitals Birmingham NHS Foundation Trust16, Maidstone Hospital17, Guy's Hospital18, Belfast Health and Social Care Trust19, Northwood University20, Mount Vernon Hospital21, Hillingdon Hospital22, University of Hull23
TL;DR: The initial results do not support routine administration of adjuvant radiotherapy after radical prostatectomy, and an observation policy with salvage radiotherapy for PSA biochemical progression should be the current standard after radical Prostate cancer.
200 citations
TL;DR: In patients with idiopathic detrusor instability there is abnormal purinergic transmission in the bladder, which may explain symptoms and this pathway may be a novel target for the pharmacological treatment of overactive bladder.
196 citations
TL;DR: To define terms and processes and agree on a minimum dataset in relation to transperineal prostate biopsy procedures and enhanced prostate diagnostics and establish a collaborative research practice.
Abstract: Objectives
To define terms and processes and agree on a minimum dataset in relation to transperineal prostate biopsy procedures and enhanced prostate diagnostics.
To identify the need for further evaluation and establish a collaborative research practice.
Patients and Methods
A 19-member multidisciplinary panel rated 66 items for their appropriateness and their definition to be incorporated into the international databank using the Research and Development/University of California Los Angeles Appropriateness Method.
The item list was developed from interviews conducted with healthcare professionals from urology, radiology, pathology and engineering.
Results
The panel agreed on 56 items that were appropriate to be incorporated into a prospective database.
In total, 10 items were uncertain and were omitted. These items were within the categories: definitions (n = 2), imaging (n = 1), surgical protocols (n = 2) and histology (n = 5).
Conclusions
The components of a minimum dataset for transperineal prostate biopsy have been defined.
This provides an opportunity for multicentre collaborative data analysis and technique development.
The findings of the present study will facilitate prospective studies into the application and outcome of transperineal prostate biopsies.
119 citations
TL;DR: To compare the expression of the seven known P2X receptors in human bladder from male patients with detrusor instability caused by symptomatic bladder outlet obstruction with that from control bladders, using a quantitative reverse transcription‐polymerase chain reaction (RT‐PCR) method.
Abstract: Objective To compare the expression of the seven known P2X receptors in human bladder from male patients with detrusor instability caused by symptomatic bladder outlet obstruction with that from control bladders, using a quantitative reverse transcription-polymerase chain reaction (RT-PCR) method.
Patients and methods Real-time quantitative RT-PCR provides a system for detecting and analysing RNA. Bladder biopsies were obtained from nine patients undergoing prostate surgery and control biopsies were obtained from eight age-matched men undergoing routine bladder endoscopy studies, and who were asymptomatic. Total RNA was extracted from each sample and 10 ng of this used for individual PCR reactions. The expression levels of the seven P2X genes in the total RNA were then determined.
Results In the control bladder, P2X1 was by far the predominant purinergic receptor at the RNA level, the remainder consistently present in the order P2X1≫ P2X4 > P2X2 > P2X7 > P2X5≫ P2X3= P2X6=0. Calponin, a smooth muscle-specific protein, was used as a marker for smooth muscle content. In bladder from symptomatic patients, the P2X1/calponin ratio was greater than that in controls (P = 0.016). There appeared to be no difference in P2X2, but P2X4, P2X5, and P2X7 were all greater in the symptomatic bladder than in the controls, although these differences were not significant.
Conclusion P2X1 is the predominant purinoceptor subtype in the human male bladder, consistent with pharmacological evidence. The amount of P2X1 receptor per smooth muscle cell is greater in the obstructed than in control bladder, suggesting an increase in purinergic function in the unstable bladder arising from bladder outlet obstruction.
110 citations
TL;DR: Large variability in performance late into the caseload demonstrates the technical difficulty of HoLEP and adjuncts to training such as simulation-based training may be of use for the new surgeon to shorten the initial phase of learning.
98 citations
Cited by
More filters
TL;DR: Findings are discussed with a specific focus on the clinical utility of cell-free nucleic acids as blood biomarkers for cancer screening, prognosis and monitoring of the efficacy of anticancer therapies.
Abstract: 1described the presence of cell-free nucleic acid (cfNA) in human blood for the first time. This attracted little attention in the scientific community and it was not until 1994 that the importance of cfNA was recognized as a result of the detection of mutated RAS gene fragments in the blood of cancer patients 2,3 (TIMELINE). In 1996, microsatellite alterations on cell-free DNA (cfDNA) were shown in cancer patients 4
2,427 citations
University of Alabama at Birmingham1, University of South Florida2, Vanderbilt University3, City of Hope National Medical Center4, Fox Chase Cancer Center5, University Of Tennessee System6, Brigham and Women's Hospital7, Seattle Cancer Care Alliance8, Case Western Reserve University9, Roswell Park Cancer Institute10, Northwestern University11, Harvard University12, University of Nebraska Medical Center13, University of Utah14, Memorial Sloan Kettering Cancer Center15
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Abstract: Ductal carcinoma in situ (DCIS) of the breast represents a heterogeneous group of neoplastic lesions in the breast ducts. The goal for management of DCIS is to prevent the development of invasive breast cancer. This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
1,545 citations
University Hospitals Birmingham NHS Foundation Trust1, University of Warwick2, University of Salford3, Cardiff University4, Institute of Cancer Research5, Beatson West of Scotland Cancer Centre6, Leeds Teaching Hospitals NHS Trust7, Weston Park Hospital8, Maidstone Hospital9, Royal Bournemouth Hospital10, Derby Hospitals NHS Foundation Trust11, Guy's Hospital12, Cheltenham General Hospital13, Queen Alexandra Hospital14, The Queen's Medical Center15, Musgrove Park Hospital16, Hull and East Yorkshire Hospitals NHS Trust17, Mount Vernon Hospital18, Royal Surrey County Hospital19, East Sussex County Council20, Western General Hospital21, Queen's University Belfast22, East Lancashire Hospitals NHS Trust23, Churchill Hospital24, Telford25, Royal Devon and Exeter Hospital26, Nottingham University Hospitals NHS Trust27, Clatterbridge Cancer Centre NHS Foundation Trust28, Swansea University29
TL;DR: Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population of men, and heterogeneity in treatment effect across prespecified subsets was not found.
1,502 citations
TL;DR: This review is focused on purinergic neurotransmission, i.e., ATP released from nerves as a transmitter or cotransmitter to act as an extracellular signaling molecule on both pre- and postjunctional membranes at neuroeffector junctions and synapses, as well as acting as a trophic factor during development and regeneration.
Abstract: This review is focused on purinergic neurotransmission, i.e., ATP released from nerves as a transmitter or cotransmitter to act as an extracellular signaling molecule on both pre- and postjunctional membranes at neuroeffector junctions and synapses, as well as acting as a trophic factor during development and regeneration. Emphasis is placed on the physiology and pathophysiology of ATP, but extracellular roles of its breakdown product, adenosine, are also considered because of their intimate interactions. The early history of the involvement of ATP in autonomic and skeletal neuromuscular transmission and in activities in the central nervous system and ganglia is reviewed. Brief background information is given about the identification of receptor subtypes for purines and pyrimidines and about ATP storage, release, and ectoenzymatic breakdown. Evidence that ATP is a cotransmitter in most, if not all, peripheral and central neurons is presented, as well as full accounts of neurotransmission and neuromodulation in autonomic and sensory ganglia and in the brain and spinal cord. There is coverage of neuron-glia interactions and of purinergic neuroeffector transmission to nonmuscular cells. To establish the primitive and widespread nature of purinergic neurotransmission, both the ontogeny and phylogeny of purinergic signaling are considered. Finally, the pathophysiology of purinergic neurotransmission in both peripheral and central nervous systems is reviewed, and speculations are made about future developments.
1,482 citations
Abstract:
1,392 citations